Desert Oasis Healthcare Partners with Rimidi to Help Improve Asthma Management for Patients using Teva Digihaler® Technology


By implementing Rimidi’s Respiratory Module, which includes integration with Teva’s Digihaler, clinical teams will be well equipped to improve their ability to make personalized, better-informed care decisions for patients with respiratory diseases

Desert Oasis Healthcare (DOHC), a leading regional medical group has implemented Rimidi’s Respiratory Module, designed to give providers a more complete view of the patient. In order to guide treatment decisions for those with respiratory diseases such as COPD or asthma, the Respiratory Module is enhanced by a collaboration with Teva Pharmaceuticals. Data from Teva’s Digihaler family of digital inhalers is brought into clinical workflows via the Rimidi platform, allowing for efficient management of COPD and asthma within the clinician’s existing electronic health record.

The implementation of the Respiratory Module with DOHC marks a unique collaboration between pharma and a clinical management platform, providing clinicians with more comprehensive data and insights about their patients’ health.

“The ability to have a streamlined, comprehensive view of a patient’s health condition allows for more efficient and personalized management,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Rimidi’s Respiratory Module incorporates clinical decision support tools to help clinicians understand potential reasons behind a patient’s uncontrolled asthma, such as not taking their medication, or not taking it properly. These factors are fundamental to achieving good asthma control but have not been easily achieved with the data and systems in place prior to the availability of Teva’s Digihaler.”

DOHC has identified 200 patients with respiratory conditions indicated for treatment with one or more of the products in Teva’s Digihaler System, and who are good candidates for enrollment via the Rimidi platform. This program is led by clinical pharmacists on DOHC’s Population Health and Prescription Management team, who are well positioned to provide patients with the proper medications as well as education and training on inhaler usage and technique.

“Our goal with this implementation is to better monitor patients with respiratory diseases across our population both in the clinic and at home, and to be able to make more personalized care decisions that may lead to more informed treatment plans,” said Lindsey Valenzuela, PharmD, APh, BCACP, Administrator of Population Health and Prescription Management at DOHC. “Rimidi’s Respiratory Module, combined with the integration of Teva’s Digihaler system, has helped us quickly identify and assess patients’ level of asthma control.”

More than 34 million Americans live with a chronic lung disease, and approximately 25 million people in the U.S. currently have asthma. Understanding more about a patient’s level of asthma control can help identify avoidable complications and an appropriate treatment.

“At Teva, we’re uniquely positioned to help the healthcare ecosystem move toward greater integration of objective health data and create meaningful population-scale solutions to help patients and providers,” said Manny Montalvo, SVP, Head of Digital Health & Innovation at Teva Pharmaceuticals. “We’re excited to help DOHC alongside Rimidi as we seek to utilize the power of technology and therapeutics to be able to predict asthma attacks.”

For more information on Rimidi’s Respiratory Disease Management Module visit